The Cognitive Effects of Radiotherapy for Brain Metastases

Eric J. Lehrer1, Brianna M. Jones1, Daniel R. Dickstein1, Sheryl Green1, Isabelle M. Germano2, Joshua D. Palmer3, Nadia Laack4, Paul D. Brown4, Vinai Gondi5, Jeffrey S. Wefel6, Jason P. Sheehan7 and Daniel M. Trifiletti8*

1 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2 Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3 Department of Radiation Oncology, Ohio State University Wexner Medical Center, Columbus, OH, United States, 4 Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States, 5 Department of Radiation Oncology, Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, IL, United States, 6 Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, United States, 7 Department of Neurological Surgery, University of Virginia, Charlottesville, VA, United States, 8 Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States

Brain metastases are the most common intracranial neoplasm and are seen in upwards of 10-30% of patients with cancer. For decades, whole brain radiation therapy (WBRT) was the mainstay of treatment in these patients. While WBRT is associated with excellent rates of intracranial tumor control, studies have demonstrated a lack of survival benefit, and WBRT is associated with higher rates of cognitive deterioration and detrimental effects on quality of life. In recent years, strategies to mitigate this risk, such as the incorporation of memantine and hippocampal avoidance have been employed with improved results. Furthermore, stereotactic radiosurgery (SRS) has emerged as an appealing treatment option over the last decade in the management of brain metastases and is associated with superior cognitive preservation and quality of life when compared to WBRT. This review article evaluates the pathogenesis and impact of cranial irradiation on cognition in patients with brain metastases, as well as current and future risk mitigation techniques.

Keywords: brain metastases, cognition, radiation therapy, radiosurgery, whole brain radiation therapy, neurosurgery, neuro-oncology, radiation oncology

INTRODUCTION

Current estimates indicate that roughly 200,000 patients are diagnosed with brain metastases annually in the United States, and 10-30% of patients with cancer receive a diagnosis of brain metastases during their disease course (1–4). These estimates may be conservative, as the true incidence is likely higher, due to a multitude of factors, such as undiagnosed brain metastasis identified on autopsy and underreporting with national registries (e.g., The National Cancer Database and Surveillance, Epidemiology, and End Results) (5, 6). Historically, patient prognosis was poor with a median overall survival of 3-4 months in patients who did not undergo surgical intervention (7). However, advancements in systemic therapy, surgery, and radiation therapy have resulted in survival advantages across multiple malignancies, thus less common and aggressive histologies are increasingly metastasizing to the brain (e.g., gastrointestinal primary cancers) (1, 8–13). Additionally, the widespread availability of MRI imaging has enhanced detection of subclinical disease.
Whole-brain radiation therapy (WBRT) is a treatment modality that has been used since the 1950s for patients with brain metastases (14). It is commonly delivered to a total dose of 30 Gy over 10 sessions. Clinicians traditionally favored WBRT due to its efficacy in providing palliation and ability to target unknown microscopic intracranial disease. WBRT has been shown to result in improved intracranial tumor control in multiple randomized trials; however, WBRT has also been shown to result in significant cognitive decline, which has been observed in up to 50% of patients following treatment (15–20). These patients can present with one or multiple cognitive domains affected, such as executive function, learning and memory, processing speed, and verbal fluency. As the prognosis in patients with brain metastases continues to improve, treatment has increasingly focused on preservation of quality of life (QOL) and cognitive function. Multiple studies have suggested that there is a correlation between neurocognitive functioning and QOL (21, 22). In recent years, the addition of memantine and hippocampal avoidance to WBRT have demonstrated significant preservation of cognitive sequelae and, in the setting of hippocampal avoidance, better preservation of patient-reported QOL, and now represent current standard of care in appropriately selected patients (17, 23, 24).

Moreover, the efficacy of brain-directed radiotherapy in providing adequate palliation has come under question in recent years. In 2016, the QUARTZ trial, which randomized 538 patients with non-small cell lung cancer brain metastases and poor prognosis, to dexamethasone with WBRT or dexamethasone with supportive care alone was published (25). This trial concluded that WBRT did not offer any benefit in QOL or survival (median survival in both arms was approximately 2 months) over supportive care, thus calling into question the efficacy of brain-directed radiotherapy in this setting. However, while broad, indiscriminate use of WBRT has fallen out of favor, it continues to be a commonly used modality in patients with a high intracranial burden of brain metastases (26, 27).

Another important advancement in the treatment of brain metastases is stereotactic radiosurgery (SRS), which is defined as the delivery of a high dose of very conformal radiation in 1-5 fractions with marked sparing of nearby healthy tissues (28). SRS has been shown to result in fewer cognitive side effects than conventional WBRT (15, 16, 18). However, WBRT has been shown to provide superior rates of intracranial control, especially by decreasing the risk of development of new brain metastases, when compared to SRS (15, 16, 18, 29). As a result, there is some controversy regarding the use of SRS in patients with large numbers of brain metastases (30, 31). Multiple studies have reported a lower risk of cognitive decline with SRS than conventional WBRT; studies comparing SRS to contemporary WBRT with neuroprotective strategies, such as memantine and hippocampal avoidance remain ongoing (32, 33).

In this article, we review the pathogenesis, diagnosis, and evaluation of cognitive decline following cranial irradiation. Additionally, we review the role of SRS, hippocampal avoidance, and memantine as risk mitigation strategies in patients undergoing cranial irradiation for brain metastases.

**PATHOGENESIS OF COGNITIVE DECLINE FOLLOWING RADIATION THERAPY**

Despite evidence showing that radiation causes cognitive impairment, the pathophysiological understanding of this common clinical scenario is poorly understood. The cause is believed to be multifactorial with changes in brain vasculature, stem-cell depletion, and changes to the brain’s microenvironment all being implicated. While damage to the hippocampus has been implicated in cognitive decline following cranial irradiation, recent evidence suggests that damage to white matter and other cortical territories, such as the frontal cortex also play a significant role (34–37).

**Cerebrovascular Damage**

Vascular pathology has been associated with many neurodegenerative diseases. It is hypothesized that one of the contributing mechanisms to Alzheimer’s Disease is the weakening of blood vessels due to the accumulation of amyloid-beta plaques in vessel walls (38). Similarly, radiation therapy can cause damage to vascular endothelial cells (39–41). In a rodent model, 10 weeks following completion of cranial irradiation to 40 Gy (5 Gy twice weekly over 4 weeks) notable changes were observed in blood vessel length and density (42). These findings suggest that ionizing radiation has the potential to cause persistent vascular damage which is frequently observed in neurocognitive diseases.

Radiation therapy can also cause blood brain barrier disruption with resultant edema (43). This can lead to abnormalities in the brain’s microenvironment and microvasculature, which have been implicated in the pathogenesis of cognitive decline (43–45). This process is largely due to apoptosis in response to increased ceramide production (46). Studies have demonstrated that radiation doses as low as 5 Gy result in the production of ceramides (46–48). Additionally, experiments using murine models have demonstrated that ionizing radiation can lead to cerebrovascular damage within the hippocampus, which persists following completion of treatment (49, 50). These findings suggest that ionizing radiation can lead to permanent dysfunction of angiogenesis in the hippocampus, which is the primary brain region responsible for learning and memory.

**Neuroanatomical Changes**

Alterations in neuronal morphology and structure has been linked to both neurological and psychiatric disorders as well as to normal aging (51). The morphology of neuronal dendritic spines, which serve as the site of synaptic transmission, are believed to play a role in neuropsychiatric disorders, as well as cognition (52, 53). Dendritic spines also contain N-methyl-D-aspartate (NMDA) glutamate receptors, which allow for calcium influx into cells, and play a major role in learning and memory. Thus, dendritic spine morphologies with greater surface area contain a higher concentration of NMDA receptors, resulting in greater synaptic strength (54, 55). Multiple studies have demonstrated that dendritic spine and

---

**Lehrer et al. Cognitive Decline Following RT BrM**

**Frontiers in Oncology** | www.frontiersin.org 2 June 2022 | Volume 12 | Article 893264
neuronal architecture play an integral role in normal aging, as well as multiple neurologic diseases and developmental disorders (56–60).

Several studies have demonstrated that ionizing radiation alters dendritic spine density and morphology, as well as neuronal architecture (61–63). In 2013, a study by Parihar et al. utilizing a murine model demonstrated significant reductions in dendritic spine complexity (>50%), frequency (20–35%), and density (40–70%) on hippocampal neurons of the dentate gyrus in response to cranial irradiation in a dose-dependent manner (63). In 2018, a study by Duman et al. using a murine model demonstrated that the administration of memantine prior to cranial irradiation can prevent radiation-induced synaptic remodeling (64). Taken together, these findings suggest that ionizing radiation can alter neuronal anatomy and NMDA receptor density, both of which are associated with cognitive decline. Additionally, memantine may play a protective role in this setting.

Impairment of Neurogenesis

The anatomical components of the hippocampus include the dentate gyrus, CA3, and CA1 regions, and the subventricular zone. The subgranular zone of the dentate gyrus is the site of hippocampal neurogenesis (65, 66). This process is an integral component of cognition and memory (67, 68). In 2013, a study by Boström et al. demonstrated that the delivery of 8 Gy to the brain of young mice resulted in decreased density of neural stem and progenitor cells, while the vasculature normalized over time (69). These findings suggest that ionizing radiation leads to decreased hippocampal neurogenesis. While the exact mechanism of neural stem cell death is not fully understood, it has been hypothesized that it occurs via apoptosis due to JNK pathway activation (70).

Neuroinflammation

Cranial irradiation activates astrocytes and microglia leading to neuroinflammation and reactive gliosis (71). Upregulation of pro-inflammatory chemokines, including CCL2, IL-6, IL-18, IL-1β, TNF-α, reactive oxygen species; and nitric oxide, in response to cranial irradiation play a major role in activation of these CNS cell types (72–74). Additionally, microglia, which normally aid in neuroprotection and synapse integrity, will release neurotoxic factor which induces neuronal cell death and contributes to cerebral edema (75, 76). Increased TNF-α activity has been shown to lead to blood brain barrier breakdown and immune cell activation (77). In 2012, a study by Belarbi et al. demonstrated that anti-TNF-α agents were able to restore neuronal function and reverse cognitive deficits due to chronic neuroinflammation in rats (73). A subsequent study demonstrated that inhibition of microglia mediated neuroinflammation in response to cranial irradiation in mice results in improved cognitive function (78). These findings suggest that neuroinflammation in response to cranial irradiation plays a key role in the pathogenesis of cognitive decline following treatment.

PATIENT PRESENTATION

It is important to note that patients with brain metastases typically have cognitive impairment at baseline before radiotherapy: a phase 3 trial with prospective cognitive testing found greater than 90% of patients had impairment on one of more cognitive tests at baseline (20). Following completion of radiotherapy, patients can present with cognitive decline as early as 1- to 6-months following treatment. Symptom presentation during this time window is potentially reversible and is believed to be due to transient demyelination (43). Patients who present at 6-months or later generally have irreversible cognitive dysfunction with multiple affected cognitive domains. These patients frequently present with deficits in attention, information processing, executive function, and learning and memory. Multiple radiographic findings, such as white matter abnormalities and changes in fractional anisotropy on diffusion tensor MRI have shown an association with cognitive decline (79–91). Consultation with neuropsychologists can be very helpful in quantifying and trending cognitive changes. Additionally, it is essential for clinicians to rule out other possible causes, such as dementia, delirium, metabolic and endocrinologic disturbances, and disease progression.

NEUROCOGNITIVE ASSESSMENT

The diagnosis of neurocognitive decline following cranial irradiation requires neuropsychological assessment. Earlier clinical trials utilized the screening test, the Mini-Mental Status Exam (MMSE); however, its use in this setting has fallen out of favor due to its limited sensitivity in diagnosing cognitive impairment (92). More commonly, clinical trials now employ neuropsychological testing that assesses multiple cognitive domains, such as executive function, learning and memory, verbal fluency, and attention. Commonly utilized cognitive assessments on randomized phase 3 clinical trials are presented in Table 1.

TREATMENT STRATEGIES TO MITIGATE THE RISK OF COGNITIVE DECLINE

Stereotactic Radiosurgery

The delivery of conventional WBRT typically involves the use of two opposed lateral radiation fields resulting in the entire brain receiving the prescription radiation dose, as shown in Figure 1A. The ability to reduce dose to areas that play a central role in neurocognition is an effective strategy to mitigate the risk of cognitive decline following irradiation. Stereotactic radiosurgery allows for the treatment of an intracranial target while largely sparing healthy surrounding tissues and, for brain metastasis, has demonstrated excellent rates of local tumor control and improved neurocognition following treatment when compared
### TABLE 1 | Phase 3 Studies Utilizing Stereotactic Radiosurgery or Memantine/Hippocampal Avoidance in Patients with Brain Metastases Incorporating Neuropsychological Testing.

| Study | Treatment Arms | Treatment Details | Cognitive Domains/Tests | Cognitive Outcomes |
|-------|----------------|-------------------|-------------------------|--------------------|
| MDACC | SRS + WBRT (n = 28) | SRS: Dose based on tumor diameter as per 90-05 (95) | Attention: WAIS-III Digit Span | Significant drop in HVLT-R Total Recall at 4 months (mean posterior probability of decline of 52% for SRS + WBRT vs 24% in SRS alone group), which was persistent at 6 months (28% vs 8%) |
| (2009) | SRS (n = 30) | • < 2 cm: 20 to 24 Gy | Processing speed: WAIS-III Digit Symbol, TMT-A Learning and memory: HVLT-R Verbal fluency: COWA | |
| | | • 2-3 cm: 18 Gy | Executive function: TMT Part B | |
| | | • 3-4 cm: 15 Gy | Upper extremity fine motor dexterity: Lafayette Grooved Pegboard | |
| | | WBRT: 30 Gy in 12 fractions | Learning and Memory: HVLT-R | |
| RTOG | WBRT + Memantine (n = 256) | WBRT: 37.5 Gy in 15 fractions | Processing speed: TMT-A | Less decline in HVLT-R Delayed Recall in memantine arm but not statistically significant at 8 weeks (p = 0.069) and at 24 weeks (p = 0.059) |
| 0614 | (2013) | Memantine: | Executive function: TMT-B | |
| | | • Week 1: 5 mg PO QD | Verbal fluency: COWA MMSE | |
| | | • Week 2: 5 mg PO QD | | |
| | | • Week 3: Morning dose increased to 10 mg | | |
| | | | Target dose for weeks 4 through 24: 10mg BID | |
| | | | | |
| N0574 | SRS + WBRT (n = 102) | SRS: 18-22 Gy WBRT: 30 Gy in 12 fractions | Learning and immediate memory: HVLT-R IR Upper extremity fine motor dexterity: Lafayette Grooved Pegboard | Less cognitive deterioration (defined as a decline of greater than 1 SD from baseline on at least 1 of the 7 cognitive tests) at 3 months after SRS alone (83.5% vs. 91.7%; p < 0.001) |
| (2016) | SRS (n = 111) | SRS: 20-24 Gy | Verbal fluency: COWA | |
| | | | Processing speed: TMT-A | |
| | | | Executive function: TMT-B | |
| | | | Executive function: TMT-B | |
| N107C | Surgery + SRS (n = 98) | SRS: 12 to 20 Gy (volume-based) | Learning and immediate memory: HVLT-R IR | Median cognition-deterioration-free survival longer after SRS to surgical cavity than after WBRT (3.7 vs 3.0 months; p < 0.0001) |
| (2017) | | • < 4.2 cm³: 20 Gy | Upper extremity fine motor dexterity: Lafayette Grooved Pegboard | |
| | | • 4.2-7.9 cm³: 18 Gy | Verbal fluency: COWA | |
| | | • 8.0-14.3 cm³: 17 Gy | Processing speed: TMT-A | |
| | | • 14.4-19.9 cm³: 15 Gy | Executive function: TMT-B | |
| | | • 20.0-29.9 cm³: 14 Gy | | |
| | | • >30.0 cm³ (up to 5 cm diameter): 12 Gy | | |
| | | WBRT: 30 Gy in 10 fractions or 37.5 Gy in 15 fractions | | |
| NRG | HA-WBRT + Memantine (n = 261) | HA-WBRT: 30 Gy in 10 fractions | Learning and memory: HVLT-R | Time to cognitive failure (defined as cognitive decline determined by reliable change index on at least one of the cognitive tests) significantly lower in HA-WBRT + memantine arm compared with WBRT + memantine arm (p = 0.03) |
| CC001 | (2020) | Memantine: Same dosing schedule as RTOG 0614 | Verbal fluency: COWA | |
| | | | Processing speed: TMT-A | |
| | | | Executive function: TMT-B | |
| | | | Executive function: TMT-B | |
| | | | | |

BID, twice daily; COWA, Controlled Oral Word Association; Gy, gray; HVLT-R, Hopkins Verbal Learning Test - Revised; LINAC, linear accelerator; MMSE, mini-mental state exam; PO, by mouth; QD, once daily; SRS, stereotactic radiosurgery; TMT-A, Trail Making Test Part A; TMT-B, Trail Making Test Part B; WAIS-III, Wechsler Adult Intelligence Scale-Third Edition; WBRT, whole-brain radiation therapy; HA-WBRT, hippocampal avoidance whole-brain radiation therapy.
Patients in the SRS arm experienced superior median cognitive-deterioration-free survival compared to the conventional WBRT arm. Additionally, no difference in overall survival were observed. Additionally, overall cognitive deterioration was higher in the conventional WBRT arm (52% vs. 85%; $p = 0.00031$). At 12-months, surgical bed control rates were 60.5% vs. 80.6% ($p = 0.00068$), favoring the conventional WBRT arm. This may be due to a large proportion of patients (40% in each arm) having a resection cavity diameter $> 3$ cm. These findings suggest that in the adjuvant setting, SRS results in improved cognitive preservation as compared to conventional WBRT. Furthermore, in the setting of larger surgical cavities or larger intact metastases, fractionated radiosurgery may be a viable alternative to maximizing local control while preserving neurocognition (94–96).

While SRS has been associated with lower rates of cognitive decline, multiple randomized controlled trials have demonstrated that SRS alone is associated with inferior local and distant brain control compared to therapeutic strategies incorporating WBRT (15, 16, 18). On the N0574 trial, time to intracranial failure was significantly shorter in the SRS compared to the SRS + conventional WBRT arm [hazard ratio (HR): 3.6; 95% confidence interval (CI): 2.2-5.9; $p < 0.001$]. Additionally, at 6 months, the local control rates were 81.6% versus 92.6%, favoring the SRS + WBRT arm ($p = 0.034$). Distant brain control rates at 6 months were 76.7% versus 94.7%, favoring the SRS + conventional WBRT arm ($p < 0.001$) (16). Similar findings were observed in the adjuvant setting on the N107C trial, where the 6-month surgical bed control was 80.4% versus 87.1%, favoring the conventional WBRT arm ($p < 0.001$) (15). Distant brain control rates at 6 months were 72.1% versus 94.6%, favoring the conventional WBRT arm ($p < 0.001$). Thus, conventional WBRT is associated with improved intracranial tumor control compared to SRS, which is likely due to irradiation of subclinical disease.

### Table 1

| Combination | Local Control | Distant Brain Control |
|-------------|---------------|-----------------------|
| SRS alone   | 81.6%         | 76.7%                 |
| SRS + WBRT  | 92.6%         | 94.7%                 |

### Figure 1

**A** Whole Brain Radiation Therapy Treatment Plan. Treatment plan for a 65-year-old woman with metastatic non-small cell lung cancer. She had a large burden of intracranial disease and was treated with WBRT to a dose of 30 Gy in 10 fractions. In WBRT, the entire brain including areas that play a major role in neurocognition receive the prescription radiation dose. The patient received memantine during and after treatment based on dosing from RTOG 0614. (Gy, gray; RTOG, radiation therapy oncology group; WBRT, whole brain radiation therapy). **B** Stereotactic Radiosurgery Treatment Plan. Treatment plan overlaid on simulation CT scan for a 50-year-old man with a history of BRAF wild-type metastatic melanoma who developed a left occipital lobe metastasis. He was treated with single fraction SRS to a dose of 20 Gy. (Gy, gray; SRS, stereotactic radiosurgery). **C** Whole Brain Radiation Therapy with Hippocampal Avoidance Treatment Plan. Treatment plan for a 60-year-old woman with metastatic breast cancer who was treated with HA-WBRT and memantine to 30 Gy in 10 fractions. Areas in red received the prescription dose, while areas in green and blue represent lower dose areas. Note the sparing of the bilateral hippocampi. (Gy, gray; HA-WBRT, hippocampal avoidance whole brain radiation therapy).
Memantine
Memantine is an antagonist of the NMDA receptor, which is a voltage-gated glutamate receptor that allows calcium entry into cells. It is presently FDA approved for use in moderate to severe Alzheimer dementia. In 2013, Brown et al. published the results of RTOG 0614, which was a phase 3 trial that randomized 508 patients with brain metastases to receive WBRT with or without the addition of memantine (17). Memantine was administered over the course of 24 weeks with the following dosing: (1) Week 1: 5 mg PO in the morning; (2) Week 2: 5 mg PO in the morning and 5 mg PO in the evening; (3) Week 3: 10 mg PO in the morning and 5 mg PO in the evening; and (4) Weeks 4-24: 10 mg in the morning and 10 mg in the evening. Patients completed formal neuropsychological testing and MMSE at regular follow-up intervals. The primary endpoint was whether memantine preserved cognitive function at 24 weeks measured by the Hopkins Verbal Learning Test – Revised (HVLT-R) Delayed Recall. The median follow-up was 12.4 months. At 24 weeks, there was less cognitive decline in the memantine arm compared to placebo; however, this was not statistically significant ($p = 0.059$). This was likely due to there only being 149 patients analyzable at 24 weeks, lowering the statistical power to detect a difference to 35%. Time to cognitive failure, which incorporated multiple cognitive domains was statistically significant and favored the memantine arm (HR: 0.784; 95% CI: 0.621-0.988; $p = 0.01$). There were no statistically significant differences in grade 3-4 toxicities, progression-free survival, or overall survival between the study arms.

While the primary endpoint was not statistically significant, these results need to be interpreted in a modern context. First, these patients were treated between 2008-2010, this was prior to the advent of immune checkpoint inhibitors, which have markedly improved survival in multiple advanced malignancies (97–101). As a result, patients treated today would be more likely to live longer and would therefore be able to complete follow-up cognitive assessments. Second, the dominant benefit in time to cognitive failure was not apparent until approximately 3 months after completing WBRT. Therefore, patients with shorter follow-up times likely had poorer baseline prognostic factors and experienced early disease progression. This suggests that memantine is likely more beneficial in patients with a better prognosis and life expectancy. Third, the primary endpoint only accounted for cognitive decline as measured by a decrease in delayed recall on the HVLT-R Delayed Recall. Therefore, time to cognitive failure, which was a composite endpoint that accounted for multiple cognitive domains is likely more clinically meaningful and did show a significant benefit with the addition of memantine to WBRT. Taken together, the findings of RTOG 0614 suggest that memantine has the potential to reduce cognitive decline in patients undergoing WBRT without an increased risk of toxicity and is therefore considered standard of care in patients receiving WBRT.

When prescribing memantine, clinicians should discuss the potential side effects, such as headache, confusion, dizziness, nausea, and agitation. Additionally, caution should be exercised when patients have a history of liver and renal impairment.

Hippocampal Avoidance
Due to the role the hippocampus plays in learning and memory, there has been a great deal of interest in sparing this region of the brain during WBRT (23, 24, 102). In 2014, Gondi et al. published the results of RTOG 0933, which was a phase 2 multi-institutional study where patients with brain metastases outside a 5 mm margin around the hippocampi received WBRT with hippocampal avoidance to a dose of 30 Gy in 10 fractions (Figure 1C) (24). There were 100 patients enrolled and all underwent formal neuropsychological testing. Enrolled patients were compared to the control arm of PCI-P-120-9801, which was a phase 3 study utilizing WBRT with identical eligibility criteria to RTOG 0933 (103). At 4 months, the mean relative decline in the modified HVLT-R Delayed Recall compared to baseline was 7%, which was significantly improved from the historical control ($p < 0.001$). In addition, cognitive results were comparable to what had been observed in prior studies of SRS (18). Similar to the findings of RTOG 0614, the benefits in cognitive preservation were seen in patients who were able to complete neuropsychological testing at 4 months. Thus, hippocampal avoidance is likely more beneficial in patients with a better baseline prognosis and life expectancy.

In 2020, Brown et al. published the results of NRG CC001, which was a phase 3 trial where patients with brain metastases were randomized to: (1) hippocampal avoidance WBRT with memantine; or (2) WBRT with memantine (23). There were 518 patients enrolled with a median follow-up of 7.9 months. All patients completed neuropsychological testing at regular intervals. The primary endpoint was time to cognitive failure, as shown in Table 1. The risk of cognitive failure favored the hippocampal avoidance arm (HR: 0.76; 95% CI: 0.60-0.98; $p = 0.03$). Additionally, at 6-months patients in the hippocampal avoidance arm had less memory complaints ($p = 0.01$), fewer cognitive symptoms ($p = 0.01$), and less symptom interference ($p = 0.008$). At 6-months, approximately 80% of patients in each arm died. This suggests that patients with a better baseline prognosis and life expectancy are likely to benefit the most from hippocampal avoidance. However, not all patients with brain metastases were eligible for inclusion on NRG CC001, such as patients with ventricular system distortion or hydrocephalus, the presence of leptomeningeal disease, and brain metastases arising from primary germ cell tumors, small cell carcinoma, an unknown primary or lymphoma. In 2021, a phase 2 randomized trial conducted in China compared WBRT with or without the use of hippocampal avoidance in patients with brain metastases (104). This trial demonstrated that hippocampal avoidance as associated with better memory preservation at 6-months compared to conventional WBRT.

Taken together, these trials suggest that in patients undergoing WBRT, the use of memantine and hippocampal avoidance reduces the risk of cognitive decline following WBRT. Additionally, these benefits are the most apparent in patients with a better baseline prognosis and life expectancy. However, not all patients are eligible for hippocampal avoidance, as no metastases are permitted within 5 mm of the bilateral hippocampi. Furthermore, hippocampal avoidance requires the use of advanced planning methods, such as intensity modulated radiation therapy and volumetric...
modulated arc therapy. Similarly, SRS requires specialized planning techniques, as well as specialized radiosurgery platforms to deliver treatment. Therefore, not all centers may have the necessary technical capabilities to deliver these treatments, particularly in underserved areas.

**FUTURE DIRECTIONS**

Preserving neurocognition in patients undergoing cranial irradiation continues to be a major area of research focus. In patients with small cell lung cancer (SCLC), prophylactic cranial irradiation (PCI) is frequently administered to a dose of 25 Gy in 10 fractions in patients with no detectable brain metastases (105–107). PCI was historically administered using conventional WBRT techniques; however, recent studies have assessed incorporating hippocampal avoidance in this setting. In 2021, the PREMER study was published, which randomized 150 patients with SCLC to standard or hippocampal avoidance PCI across 13 institutions in Spain (108). At 3-months the investigators observed that the decline in memory favored the hippocampal avoidance arm (5.8% vs. 23.5%; \( p = 0.003 \)). However, in 2021, a phase 3 trial conducted in the Netherlands did not observe a lower probability of cognitive decline in the hippocampal avoidance PCI arm (109). The NRG CC003 trial is presently investigating this hypothesis in North America and will be completing accrual later this year (110).

While there is strong evidence supporting the role of SRS in the management of limited numbers of brain metastases (15, 16, 18), the use of SRS remains controversial in the management of larger numbers of lesions. In 2020, a study by Rinna et al. observed that in patients undergoing Gamma Knife® SRS that 10 or more metastases, and metastases in close proximity to the hippocampi were at an increased risk for excessive hippocampal dosing (111). In 2021, a study published by Burgess et al. evaluating 60 SRS plans with a median distance to the hippocampus of 2.4 cm observed that patients can undergo replanning to decrease the hippocampal dose by > 50% without compromising target coverage (112). Taken together, these findings suggest that limiting dose to the hippocampus during SRS may further decrease the risk of cognitive decline in these patients.

CCGT GE.7 is an ongoing phase 3 trial that is randomizing patients with 5–15 brain metastases to SRS or WBRT with the addition of memantine and hippocampal avoidance (33). There is ongoing prospective investigation into the role that regions outside of the hippocampus play in cognitive decline following cranial irradiation (113). There is presently a trial underway at Johns Hopkins University investigating neurocognitive functioning with sparing of the genu of the corpus callosum during WBRT for brain metastases (114). Another study underway at the University of California San Diego is investigating sparing of white matter tracts during SRS for brain metastases (115).

In recent years, brain metastasis velocity, which describes the recurrence rate of new brain metastases following treatment with SRS had become a validated prognostic metric (116). NRG BN009 is a phase 3 trial comparing salvage SRS to SRS with hippocampal avoidance WBRT with the addition of memantine in patients with a first or second distant relapse following upfront SRS and a brain metastasis velocity of 4 or higher (32).

**CONCLUSION**

Cognitive decline is a common clinical manifestation observed in patients who undergo WBRT for brain metastases. Strategies, such as SRS and the addition of memantine and/or hippocampal avoidance to WBRT are excellent treatment options to mitigate this risk. Studies are underway that will allow for further application of these treatments, as well as defining the role that other brain regions play in the pathogenesis of cognitive decline following cranial irradiation.

**AUTHOR CONTRIBUTIONS**

Conceptualization: EL, DT. Supervision: DT. Writing – original draft: EL, BJ, DR. Writing – review and editing: All authors. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol* (2004) 22(14):2865–72. doi: 10.1200/JCO.2004.12.149
2. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous System. *J Natl Cancer Inst* (2011) 103(9):714–36. doi: 10.1093/jnci/djp077
3. Singh R, Stoltzfus KC, Chen H, Louie AV, Lehrer EL, Horn SR, et al. Epidemiology of Synchronous Brain Metastases. *Neurooncol Adv* (2020) 2(1):vdaa041. doi: 10.1093/nnao/vdaa041
4. Lehrer EL, Stoltzfus KC, Jones BM, Giusani NJ, Walter V, Wang M, et al. Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. *Am J Clin Oncol* (2021) 44:572–9. doi: 10.1097/COC.0000000000000866
5. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. Nccn Practice Guidelines in Oncology - Central Nervous System Cancers, Version 1.2017. *J Natl Compr Cancer Netw* (2017) 15:1331–45. doi: 10.6004/jnccn.2017.0166
6. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, et al. Updates in the Management of Brain Metastases. *Neuro Oncol* (2016) 18(8):1043–65. doi: 10.1093/neuonc/now127
7. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, Patterns of Care, and Survival in Patients With Brain Metastases: What Has Changed in the Last 20 Years? *Cancer* (2011) 117(11):2505–12. doi: 10.1002/cncr.25707
8. Sanghvi SM, Lieschka JW, Cai L, Collins S, Nair M, Collins B, et al. Clinical Outcomes of Gastrointestinal Brain Metastases Treated With Radiotherapy. *Radiat Oncol* (2017) 12(1):43. doi: 10.1186/s13014-017-0774-3
9. Trifiletti DM, Patel N, Lee CC, Romano AM, Sheehan JP. Stereotactic Radiosurgery in the Treatment of Brain Metastases From Gastrointestinal Primaries. *J Neurooncol* (2015) 124(3):439–46. doi: 10.1007/s11060-015-1857-3
10. Lehrer EJ, Gurewitz J, Bernstein K, Patel D, Kondziolka D, Niranjan A, et al. Radiation Necrosis in Renal Cell Carcinoma Brain Metastases Treated With Checkpoint Immunitors and Radiotherapy: An International Multicenter Study. *Cancer* (2022) 128:1429–38. doi: 10.1002/cncr.34087

11. Lehrer EJ, McGee HM, Peterson JL, Vallow L, Ruiz-Garcia H, Zaorsky NG, et al. Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. *Int J Mol Sci* (2018) 19(10). doi: 10.3390/ijms19103054

12. Lehrer EJ, McGee HM, Sheehan JP, Trifiletti DM. Integration of Immuno-Oncology With Stereotactic Radiosurgery in the Management of Brain Metastases. *J Neuro Oncol* (2021) 151(1):75–84. doi: 10.1007/s12074-020-03427-6

13. Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quinones-Hinojosa A, Zaorsky NG, et al. Treatment of Brain Metastases With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors: An International Meta-Analysis of Individual Patient Data. *Radiother Oncol* (2019) 130:104–12. doi: 10.1016/j.radonc.2018.08.025

14. Chao JH, Phillips R, Nickson JJ. Roentgen-Ray Therapy of Cerebral Metastases. *Cancer* (1954) 7(4):682–9. doi: 10.1002/1097-0142(195407)7(4):682[AID-CNCR280070409-3.0.CO;2-S]

15. Brown PD, Ballman KV, Cerhan JH, Anderson SK, et al. Postoperative Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy for Resected Metastatic Brain Disease (Nctg N107C/Coc 3): A Multicentre, Randomised, Controlled, Phase 3 Trial. *Lancet Oncol* (2017) 18(8):1049–60. doi: 10.1016/S1470-2045(17)30441-2

16. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Radiation-Induced Brain Injury: A Review. *Front Oncol* (2012) 2:73. doi: 10.3389/fonc.2012.00073

17. Myers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Postoperative Stereotactic Radiosurgery Compared With Whole-Brain Radiation in Patients With Brain Metastasis. *Neurol Oncol* (2009) 11(10):1037–44. doi: 10.1016/S1470-2045(09)70263-3

18. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-Induced Brain Injury: A Review. *Front Oncol* (2012) 2:73. doi: 10.3389/fonc.2012.00073

19. Mahajan A, Ahmed S, McAleer MF, Weingberg JS, Li J, Brown P, et al. Post-Operative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: A Single-Centre, Randomised, Controlled, Phase 3 Trial. *Lancet Oncol* (2017) 18(8):1040–8. doi: 10.1016/S1470-2045(17)30414-X

20. Weintraub NL, Jones WK, Manka D. Understanding Radiation-Induced Vascular Disease. *J Alzheimers Dis* (2020) 76. doi: 10.3231/jad.2020.760391

21. Connor M, Karunamuni R, McDonald C, Seibert T, White N, Moiseenkov V, et al. Regional Susceptibility to Dose-Dependent White Matter Damage After Brain Radiotherapy. *Radiother Oncol* (2017) 123(2):209–17. doi: 10.1016/j.radonc.2017.04.006

22. Acharya S, Guo Y, Patni T, Li Y, Wang C, Gargone M, et al. Association Between Brain Substructure Dose and Cognitive Outcomes in Children With Medulloblastoma Treated on Sjb03: A Step Toward Substructure-Informed Planning. *J Clin Oncol* (2022) 40(1):83–93. doi: 10.1200/JCO.21.01480

23. Solis EJr., Hascup KN, Hascup ER, Alzheimer’s Disease: The Link Between Amyloid-Beta and Neurovascular Dysfunction. *J Alzheimer’s Dis* (2020) 76(4):1179–98. doi: 10.3233/JAD-200473

24. Weintraub NL, Jones WK, Manka D. Understanding Radiation-Induced Vascular Disease. *J Am Coll Cardiol* (2010) 55(12):1237–9. doi: 10.1016/j.jacc.2009.11.053

25. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and Supportive Care With or Without Whole Brain Radiotherapy in Treating Patients With Non-Small Cell Lung Cancer With Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy (Quartz): Results From a Phase 3, Non-Inferiority, Randomised Trial. *Lancet* (2016) 388(10055):2004–14. doi: 10.1016/S0140-6736(16)30825-X

26. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for Brain Metastases: Asco-Sno-Astro Guideline. *J Clin Oncol* (2022) 40(5):492–516. doi: 10.1200/JCO.2021.02314

27. Lehrer EJ, Snyder MH, Desai BD, Li CE, Narayan A, Trifiletti DM, et al. Clinical and Radiographic Adverse Events After Gamma Knife Radiosurgery for Brainstem Lesions: A Dosimetric Analysis. *Radiother Oncol* (2020) 147:200–9. doi: 10.1016/j.radonc.2020.05.010

28. Triplite DM, Sheehan JP, Grover S, Dutta SW, Rusthoven CG, Kavanagh BD, et al. National Trends in Radiotherapy for Brain Metastases at Time of Diagnosis of Non-Small Cell Lung Cancer. *J Clin Neurosci* (2017) 45:48–53. doi: 10.1016/j.jocn.2017.08.028

29. Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quinones-Hinojosa A, Zaorsky NG, et al. Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (Rtog 0933): A Phase II Multi-Institutional Trial. *J Clin Oncol* (2014) 32(34):3810–6. doi: 10.1200/JCO.2014.57.2909

30. Lehrer EJ, Gurewitz J, Bernstein K, Patel D, Kondziolka D, Niranjan A, et al. Radiation Necrosis in Renal Cell Carcinoma Brain Metastases Treated With Checkpoint Immunitors and Radiotherapy: An International Multicenter Study. *Cancer* (2022) 128:1429–38. doi: 10.1002/cncr.34087

31. Lehrer EJ, McGee HM, Sheehan JP, Trifiletti DM. Integration of Immuno-Oncology With Stereotactic Radiosurgery in the Management of Brain Metastases. *J Neuro Oncol* (2021) 151(1):75–84. doi: 10.1007/s12074-020-03427-6
42. Brown WR, Thore CR, Moody DM, Robbins ME, Wheeler KT. Vascular Damage After Fractionated Whole-Brain Irradiation in Rats. Radiat Res (2005) 163(4):385–90. doi: 10.1667/RR3098.1

43. Cramer CK, Cummings TL, Andrews RN, Stroud R, Rapp SR, Shaw EG, et al. Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients. Curr Treat Options Oncol (2019) 20(5):42. doi: 10.1007/s11864-019-0641-6

44. Li YQ, Chen P, Haimovitz-Friedman A, Reilly RM, Wong CS. Endothelial Apoptosis Initiates Acute Blood-Brain Barrier Disruption After Ionizing Radiation. Cancer Res (2003) 63(18):5950–6.

45. Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-Brain Barrier Permeability of Gefitinib in Patients With Metastases From Non-Small-Cell Lung Cancer Before and During Whole Brain Radiation Therapy. Oncotarget (2015) 6(10):8366–76. doi: 10.18632/oncotarget.13877

46. Baselet B, Sonoveux P, Raout S, Aerts A. Pathological Effects of Ionizing Radiation: Endothelial Activation and Dysfunction. Cell Mol Life Sci (2019) 76(4):699–728. doi: 10.1007/s00018-019-2956-z

47. Haimovitz-Friedman A, Kan CC, Elieher D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing Radiation Acts on Cellular Membranes to Generate Ceramide and Initiate Apoptosis. J Exp Med (1994) 180(2):253–35. doi: 10.1084/jem.180.2.325

48. Kolesnich R, Fuks Z. Radiation and Ceramide-Induced Apoptosis. Oncogene (2003) 22(37):3897–906. doi: 10.1038/sj.onc.1206706

49. Warrington JP, Csiszar A, Mitschelen M, Sonntag WE, Sunoyagi J, Kerstens P, et al. Automatic Dendritic Spine Quantification on Neurolucida 360. Neurol. 

50. Warrington JP, Csiszar A, Johnson DA, Herman TS, Ahmad S, Lee YW, et al. Cerebral Microvascular Rarefaction Induced by Whole Brain Radiation Is Reversible by Systemic Hymisc in Mice. Am J Physiol Heart Circ Physiol (2011) 300(3):H736–44. doi: 10.1152/ajpheart.01024.2010

51. Forrest MP, Parnell E, Penzes P. Dendritic Structural Plasticity and Neuropsychiatric Disease. Nat Rev Neurosci (2018) 19(4):215–34. doi: 10.1038/s41571-018-0016-3

52. Pchitskaya E, Bezprozvanny I. Dendritic Spines Shape Analysis—Classification or Clusterization? Perspective. Front Synaptic Neurosci (2020) 12:31. doi: 10.3389/fnyns.2020.00031

53. Dickstein DL, Dickstein DR, Janssen WGM, Hof PR, Glaser JR, Rodriguez A, et al. Automatic Dendritic Spine Quantification From Confocal Data With Neuronlucida 360. Curr Proteo Neurosci (2016) 7:1. 27 1–11. doi: 10.1002/cpn.16

54. Luscher C, Malenka RC. Nmda Receptor-Dependent Long-Term Potentiation and Long-Term Depression (Ltp/Ltd). Front Synaptic Neurosci (2011) 4:26. doi: 10.1002/cnsc.2013.1

55. Villalba RM, Smith Y. Loss and Remodeling of Striatal Dendritic Spines in Parkinson’s Disease: From Homeostasis to Maladaptive Plasticity? J Neurotransm (Vienna) (2018) 125(3):431–47. doi: 10.1007/s00702-017-1735-6

56. Martinez-Cerdeno V. Dendrite and Spine Morphology and Density Through Reduction of Cytoskeletal Proteins in Mature Neurons. Radiat Res (2013) 179(6):630–6. doi: 10.1667/RR3098.1

57. Parikh VK, Limoli CL. Cranial Irradiation Compromises Neural Architecture in the Hippocampus. Proc Natl Acad Sci USA (2013) 110(31):12822–7. doi: 10.1073/pnas.1307301110

58. Duman JG, Dinh J, Zhou W, Cham H, Mavratsas VC, Pavekovic M, et al. Memantine Prevents Acute Radiation-Induced Toxicities at Hippocampal Excitatory Synapses. Neuro Oncol (2018) 20(5):655–65. doi: 10.1093/neuonc/nox203

59. Kempermann G, Kuhn HG, Gage FH. More Hippocampal Neurons in Adult Mice Living in an Enriched Environment. Nature (1997) 386(6624):493–5. doi: 10.1038/s41571-018-0016-3

60. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the Dentate Gyrus of the Adult Rat: Age-Related Decrease of Neuronal Progenitor Proliferation. J Neurosci (1996) 16(6):2027–33. doi: 10.1523/JNEUROSCI.16-06-02027.1996

61. Chakraborti A, Allen A, Allen B, Rosi S, Fike JR. Cranial Irradiation Alters Dendritic Spine Density and Morphology in the Hippocampus. PLoS One (2012) 7(7):e40844. doi: 10.1371/journal.pone.0040844

62. Shirai K, Mizui T, Suzuki Y, Okamoto M, Hanamura K, Yoshida Y, et al. X Irradiation Changes Dendritic Spine Morphology and Density Through

Frontiers in Oncology | www.frontiersin.org June 2022 | Volume 12 | Article 8932649

Lehrer et al. Cognitive Decline Following RT BrM

9
Biomarkers. JAMA Neurol (2014) 71(7):855–62. doi: 10.1001/jamaneurol.2014.754

81. Capuzzo A, Acopian L, Bekinschin T, Furman M, Gomila H, Martinez A, et al. White Matter Hyperintensities Are Significantly Associated With Cortical Atrophy in Alzheimer’s Disease. J Neurol Neurosurg Psychiatry (2004) 75(6):822–7. doi: 10.1136/jnnp.2003.019273

82. Brickman AM, Muraskin J, Zimmerman ME. Structural Neuroimaging in Alzheimer’s Disease: Do White Matter Hyperintensities Matter? Dialogues Clin Neurosci (2009) 11(2):181–90. doi: 10.3187/dcn09.11.2/ambrickman

83. Brickman AM, Honig LS, Scarneam N, Tatarina O, Sanders L, Albert MS, et al. Measuring Cerebral Atrophy and White Matter Hyperintensity Burden to Predict the Rate of Cognitive Decline in Alzheimer Disease. Arch Neurol (2008) 65(9):1202–8. doi: 10.1001/archneur.65.9.1202

84. Brickman AM. Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities. Curr Neurol Neurosci Rep (2013) 13(12):415. doi: 10.1007/s11910-013-0415-7

85. Johannesen TB, Lien HH, Hole KH, Lote K. Radiological and Clinical Assessment of Long-Term Brain Tumor Survivors After Radiotherapy. Radiother Oncol (2003) 69(2):169–76. doi: 10.1016/s0167-8140(03)00192-0

86. Constine LS, Konski A, Ekholm S, McDonald S, Rubin P. Adverse Effects of Brain Irradiation Correlated With Mr and Ct Imaging. Int J Radiat Oncol Biol Phys (2012) 82(5):2033–40. doi: 10.1016/j.ijrobp.2011.01.068

87. Chung PH, Tsai Y, Nazem-Zaedah M, Tyo O, Bucelh HA, Tsien CI, et al. Diffusion Tensor Imaging Predicts Cognitive Function Change Following Partial Brain Radiotherapy for Low-Grade and Benign Tumors. Radiother Oncol (2016) 120(2):234–40. doi: 10.1016/j.radonc.2016.06.021

88. Mabbott DJ, Noseworthy MD, Bouffet E, Rockel C, Laughlin S. Diffusion Tensor Imaging of White Matter After Cranial Radiation in Children for Medulloblastoma: Correlation With IQ. Neuro Oncol (2006) 8(3):244–52. doi: 10.1215/15228517-2006-002

89. Laukkainen E, Klonoff H, Allan B, Graeb D, Murray N. The Role of Prophylactic Brain Irradiation in Limited Stage Small Cell Lung Cancer: Clinical, Neuropsychologic, and Ct Sequelae. Int J Radiat Oncol Biol Phys (1988) 14(6):1109–17. doi: 10.1016/0360-3016(88)90286-0

90. Meyers CA, Wefel JS. The Use of the Mini-Mental State Examination to Assess Cognitive Functioning in Cancer Trials: No Ifs, Ands, Buts, or Buts. J Clin Oncol (2003) 21(13):2529–36. doi: 10.1200/JCO.2003.12.122

91. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Hippocampal-Sparing in Gamma Knife Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. Int J Radiat Oncol Biol Phys (2013) 85(2):348–54. doi: 10.1016/j.ijrobp.2012.11.031

92. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh R, Wu W, et al. Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. J Clin Oncol (2003) 21(13):2529–36. doi: 10.1200/JCO.2003.12.122

93. Yang WC, Chen YE, Yang CC, Wu PF, Chan HM, Chen JL, et al. Hippocampal Avoidance Whole-Brain Radiotherapy Without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase Ii Blinded Randomized Trial. Neuro Oncol (2021) 23(3):478–86. doi: 10.1093/neuonc/noaa193

94. Slotman B, Fairev-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. N Engl J Med (2007) 357(7):664–72. doi: 10.1056/NEJMoa071780

95. Asperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic Cranial Radiation for Patients With Small-Cell Lung Cancer in Complete Remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 341(7):746–84. doi: 10.1056/NEJM199906143410703

96. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic Cranial Irradiation Versus Observation in Patients With Extensive-Disease Small-Cell Lung Cancer: A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol (2017) 18(5):663–71. doi: 10.1016/S1470-2045(17)30239-9

97. Rodriguez de Dios N, Counago F, Murcia-Mejía M, Rico-Oses M, Calvo-Peña P, Samper P, et al. Randomized Phase Ii Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (Premier): A Gicor-Goeccp-Seor Study. J Clin Oncol (2021) 39(28):3118–27. doi: 10.1200/JCO.21.00639

98. Lehrer EJ, Peterson JL, Zaorsky NG, Mohsin MA, Decock CL, Veit RM, et al. Pembrolizumab VS Chemotherapy for Pd-I1-Positive Non-Small-Cell Lung Cancer. N Engl J Med (2016) 375(19):1823–33. doi: 10.1056/NEJMoa1600774

99. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(2):123–35. doi: 10.1056/NEJMoa1504627

100. Borgheei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(17):1627–39. doi: 10.1056/NEJMoa1507643

101. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gunus M, Mazieres J, et al. Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med (2018) 379(21):2040–51. doi: 10.1056/NEJMoa1810865

102. Gondi V, Herrmann BP, Mehta MP, Tome WA. Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors. Int J Radiat Oncol Biol Phys (2013) 85(2):348–54. doi: 10.1016/j.ijrobp.2012.11.031

103. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh R, Wu W, et al. Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. J Clin Oncol (2003) 21(13):2529–36. doi: 10.1200/JCO.2003.12.122

104. Yang WC, Chen YE, Yang CC, Wu PF, Chan HM, Chen JL, et al. Hippocampal Avoidance Whole-Brain Radiotherapy Without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase Ii Blinded Randomized Trial. Neuro Oncol (2021) 23(3):478–86. doi: 10.1093/neuonc/noaa193
114. Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases. Available at: https://ClinicalTrials.gov/show/NCT03223922.

115. Ucsd Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases. Available at: https://ClinicalTrials.gov/show/NCT04343157.

116. McTyre ER, Soike MH, Farris M, Ayala-Peacock DN, Hepel JT, Page BR, et al. Multi-Institutional Validation of Brain Metastasis Velocity, a Recently Defined Predictor of Outcomes Following Stereotactic Radiosurgery. *Radiother Oncol* (2020) 142:168–74. doi: 10.1016/j.radonc.2019.08.011

**Conflict of Interest:** PB reports contribution to UpToDate outside of the submitted work. JW is on the advisory board of Bayer, he serves as a consultant to Angiochem, Bayer, Juno, Novocure, Vanquish Oncology, and GT Medical technologies. JP reports research funding and honoraria from Varian and research funding from Genentech, NIH, and Kroger; he serves on the advisory board of Novocure. IM serves as a consultant to BrainLab and Integra; DT reports institutional support from Novocure Ltd and consulting for Boston Scientific Corporation outside to the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lehrer, Jones, Dickstein, Green, Germano, Palmer, Laack, Brown, Gondi, Wefel, Sheehan and Trifiletti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.